

Revance Therapeutics, Inc.
 Form 4
 February 11, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Glasheen James Walter

(Last) (First) (Middle)

C/O TECHNOLOGY PARTNERS, 100 SHORELINE HWY, BLDG B, STE 282

(Street)

MILL VALLEY, CA 94941

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 Revance Therapeutics, Inc. [RVNC]

3. Date of Earliest Transaction
 (Month/Day/Year)
 02/11/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/11/2014		C	16,703 ⁽¹⁾	A <u>(2)</u> 16,703	I	by Technology Partners Affiliates VII, L.P. ⁽³⁾
Common Stock	02/11/2014		X	149 ⁽⁴⁾	A <u>(4)</u> 16,852	I	by Technology Partners Affiliates VII, L.P. ⁽³⁾
	02/11/2014		C		A <u>(2)</u> 622,648	I	

Edgar Filing: Revance Therapeutics, Inc. - Form 4

Common Stock				622,648 <u>(5)</u>					by Technology Partners Fund VII, L.P. <u>(6)</u>
Common Stock	02/11/2014		C	34,427 <u>(7)</u>	A	<u>(7)</u>	657,075	I	by Technology Partners Fund VII, L.P. <u>(6)</u>
Common Stock	02/11/2014		X	52,087 <u>(4)</u>	A	<u>(4)</u>	709,162	I	by Technology Partners Fund VII, L.P. <u>(6)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount of Shares
Series E-1 Convertible Preferred Stock	<u>(2)</u>	02/11/2014		C	5,231	<u>(2)</u> <u>(2)</u>	Common Stock	5,231	
Series E-1 Convertible Preferred Stock	<u>(2)</u>	02/11/2014		C	81,959	<u>(2)</u> <u>(2)</u>	Common Stock	81,959	
Series E-2 Convertible Preferred Stock	<u>(2)</u>	02/11/2014		C	4,125	<u>(2)</u> <u>(2)</u>	Common Stock	4,125	

Edgar Filing: Revance Therapeutics, Inc. - Form 4

Series E-2 Convertible Preferred Stock	<u>(2)</u>	02/11/2014	C	73,275	<u>(2)</u>	<u>(2)</u>	Common Stock	73,275
Series E-3 Convertible Preferred Stock	<u>(2)</u>	02/11/2014	C	4,546	<u>(2)</u>	<u>(2)</u>	Common Stock	4,546
Series E-3 Convertible Preferred Stock	<u>(2)</u>	02/11/2014	C	74,665	<u>(2)</u>	<u>(2)</u>	Common Stock	74,665
Series E-4 Convertible Preferred Stock	<u>(2)</u>	02/11/2014	C	2,801	<u>(2)</u>	<u>(2)</u>	Common Stock	2,801
Series E-4 Convertible Preferred Stock	<u>(2)</u>	02/11/2014	C	303,563	<u>(2)</u>	<u>(2)</u>	Common Stock	303,563
Series E-5 Convertible Preferred Stock	<u>(2)</u>	02/11/2014	C	89,186	<u>(2)</u>	<u>(2)</u>	Common Stock	89,186
Convertible Promissory Notes	<u>(7)</u>	02/11/2014	C	34,427 <u>(7)</u>	<u>(7)</u>	<u>(7)</u>	Common Stock	34,427 <u>(7)</u>
Warrant to Purchase Common Stock	<u>(8)</u>	02/11/2014	X	149	<u>(8)</u>	<u>(8)</u>	Common Stock	149
Warrant to Purchase Common Stock	<u>(8)</u>	02/11/2014	X	52,087 <u>(9)</u>	<u>(8)</u>	<u>(8)</u>	Common Stock	52,087 <u>(9)</u>

